SHAPE Versus Milligan-Morgan Hemorrhoidectomy for Hemorrhoidal Disease

ConditionHemorrhoid
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCairo University

About this trial

This study will be conducted at the General Surgery Department, Kasr Al-Ainy Teaching Hospital, Cairo University, on patients presenting with third- and fourth-degree hemorrhoids. Adult patients older than 18 years who fulfill the inclusion criteria and provide informed consent will be enrolled. Patients with inflammatory bowel disease, anal stenosis, colorectal malignancy, or fecal incontinence will be excluded.

All patients will undergo detailed preoperative assessment including medical and surgical history, evaluation of anal symptoms, local anorectal examination, digital rectal examination, and routine laboratory investigations.

Participants will be randomized into two groups: Group A will undergo Skin-Sparing Hemorrhoidectomy and PExy (SHAPE), while Group B will undergo conventional Milligan-Morgan hemorrhoidectomy.

Postoperatively, oral fluids will be allowed after 2 hours and normal diet resumed as tolerated. Patients will be discharged on the first postoperative day unless otherwise indicated. Follow-up visits will assess postoperative pain, complications, and surgical outcome

Eligibility criteria

Qualifiers

All patients with third- and fourth-degree piles, and their age greater than 18 years old

Disqualifiers

Patients with inflammatory bowel disease.

Patients with anal stenosis

Patients with colorectal malignancy

Patient with fecal incontinence

Trial design

Treatments tested in this trial

  • Skin Sparing Hemorrhoidectomy and PExy (SHAPE)
  • Milligan-Morgan Hemorrhoidectomy

Treatment groups

68 Participants
are divided into 2 treatment groups

Sponsors and collaborators